News | December 28, 2021
CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
It plans to deliver over 300 million doses to the Indian government
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The company will market it under the brand name Molflu
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Subscribe To Our Newsletter & Stay Updated
